Search
Pazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalIt is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Hydrochlorothiazide
go.drugbank.com/drugs/DB00999ApprovedInvestigationalVet approved[L7426,L7459] Hydrochlorothiazide was granted FDA approval on 12 February 1959.[L8444]
Mixtures: OLMETEC PLUS 20/25MG FTA, OLMETEC PLUS 20/25MG FTAAcetrizoic acid
go.drugbank.com/drugs/DB09347ApprovedWithdrawn[L1704] Acetrizoic acid presents, in the FDA records, a category of drug substance with an inactive status.[L1703] … [A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978.
Tapentadol
go.drugbank.com/drugs/DB06204ApprovedInvestigational[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011.
Cemiplimab
go.drugbank.com/drugs/DB14707ApprovedInvestigational[L39804] Cemiplimab was first approved by the FDA on September 28, 2018, as the first FDA-approved treatment for advanced cutaneous squamous cell carcinoma (CSCC).
Codeine
go.drugbank.com/drugs/DB00318ApprovedIllicitInvestigationalThe relief of pain (analgesia) is a primary goal for enhancing the quality of life of patients and for increasing the ability of patients to engage in day to day activities. Codeine, an opioid analgesic, was originally approved in the US...
Amiodarone
go.drugbank.com/drugs/DB01118ApprovedInvestigationalAmiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpat...
Nadofaragene firadenovec
go.drugbank.com/drugs/DB17381ApprovedInvestigationalMost patients with this condition undergo radical cystectomy since other non-surgical treatments are far less effective. … It is the first gene therapy approved by the FDA for the treatment of bladder cancer.[L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat.
Regadenoson
go.drugbank.com/drugs/DB06213ApprovedInvestigationalManufactured by Astellas and FDA approved April 10, 2008.
Dextroamphetamine
go.drugbank.com/drugs/DB01576ApprovedIllicitInvestigationalDextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]